Celon Pharma Announces Successful Completion of Phase 1A Trial of CPL’116, JAK-ROCK Inhibitor
Retrieved on:
Wednesday, February 10, 2021
KIELPIN, Poland, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Celon Pharma S.A. today announced the successful completion of its Phase 1A trial of its JAK/ROCK kinases dual inhibitor, CPL116.
Key Points:
- KIELPIN, Poland, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Celon Pharma S.A. today announced the successful completion of its Phase 1A trial of its JAK/ROCK kinases dual inhibitor, CPL116.
- No adverse events associated with administration of the investigational drug were observed, and the trial met its primary endpoint.
- Celon Pharma is an integrated biopharmaceutical company which designs, develops, manufactures and distributes pharmaceutical products.
- It has been listed on the Warsaw Stock Exchange since 2016. www.celonpharma.com
This press release (Press release) has been prepared by Celon Pharma S.A. (the Company).